If you have ever noticed the quiet euphoria of a long run, the warm focus of a creative flow state, or the easy contentment after a shared meal with friends, you have already met anandamide. It is the endogenous cannabinoid most researchers point to when explaining why the brain has an entire receptor system tuned to plant compounds like CBD and THC. Understanding anandamide — and the wider endocannabinoid system (ECS) it belongs to — is the most reliable way to make sense of the dozens of phytocannabinoid products now appearing on South African shelves.
Discovery: How a Receptor Found Its Own Ligand
The endocannabinoid system was, in a sense, discovered backwards. In the late 1980s and early 1990s, researchers at the National Institutes of Health and the Hebrew University of Jerusalem cloned and characterised two G-protein-coupled receptors — CB1 and CB2 — that bind delta-9-tetrahydrocannabinol (THC), the principal psychoactive compound in cannabis. The receptors were there, in the brain and on immune cells. The question was: what does the body make that fits them?
Two lipid-derived agonists were identified within a few years of each other. The first, isolated from pig brain in 1992 by Raphael Mechoulam's group, was arachidonoylethanolamide — given the Sanskrit-rooted name anandamide, after "ananda", the word for bliss. The second, 2-arachidonoylglycerol (2-AG), was identified in 1995 in both gut and brain tissue. Together, anandamide and 2-AG are the two principal endocannabinoids: the body's own keys to the cannabinoid locks.
Excellent overviews of the discovery pathway and the receptor pharmacology that followed are collected on the PubMed endocannabinoid review collection, and on PubMed Central's open-access archive. Anyone writing about ECS pharmacology in 2026 is standing on three decades of mechanistic work.
The Receptor Map: CB1, CB2, and the Extended Network
CB1 receptors are the most abundant G-protein-coupled receptors in the mammalian brain, concentrated in the cortex, hippocampus, basal ganglia, cerebellum, and hypothalamus. They sit on the presynaptic terminals of neurons, where their activation typically suppresses further neurotransmitter release — a feedback brake on signalling. CB2 receptors are found predominantly on immune cells (microglia, splenocytes, peripheral macrophages), on bone cells, and at lower density in some brain regions under inflammatory conditions.
Anandamide is a partial agonist at CB1 with relatively weak activity at CB2, while 2-AG is a full agonist at both. The behavioural fingerprint of anandamide is shorter-lived than 2-AG: it is rapidly cleared by the enzyme fatty acid amide hydrolase (FAAH), whereas 2-AG is hydrolysed mainly by monoacylglycerol lipase (MAGL). That difference in half-life matters when researchers ask whether an observed effect was driven by anandamide signalling or by the broader 2-AG system.
Beyond CB1 and CB2, anandamide and related N-acylethanolamines also act on transient receptor potential (TRPV1) channels, on peroxisome proliferator-activated receptors (PPARs), and on a handful of non-cannabinoid orphan GPCRs. The ECS is therefore not a clean two-receptor story; it is a lipid signalling network with overlapping affinities. ClinicalTrials.gov lists ongoing human studies that target FAAH inhibition as an indirect way to elevate endogenous anandamide — a research pathway distinct from administering phytocannabinoids directly.
What Anandamide Actually Does: Mood, Memory, Appetite, and Pain
The behavioural effects of anandamide administration in animal models are consistent with a compound that modulates stress, reward, and forgetting. Central infusion produces anxiolytic-like responses in the elevated plus maze; CB1 antagonists such as rimonabant block these effects, confirming receptor mediation. In feeding studies, anandamide and 2-AG both stimulate appetite via hypothalamic circuits, which is one mechanistic reason cannabis is associated with the "munchies" — but the same circuits, when dysregulated, appear in research on obesity and metabolic syndrome.
Memory is the most counterintuitive domain. Endocannabinoids are produced on demand in a retrograde fashion: a postsynaptic neuron synthesises anandamide or 2-AG in response to strong calcium influx, and the lipid travels backward across the synapse to suppress presynaptic release. This depolarisation-induced suppression of inhibition (DSI) and excitation (DSE) is a core mechanism of synaptic plasticity. The working model is that anandamide helps the brain forget the irrelevant while consolidating the salient — a useful framing for any researcher thinking about PTSD, addiction, or fear-extinction paradigms. The mechanistic case is reviewed in the PubMed retrograde-signalling collection.
Pain modulation is the fourth pillar. Anandamide and 2-AG both attenuate nociceptive signalling at spinal and supraspinal sites, and FAAH inhibitors — which raise endogenous anandamide — show analgesic activity in rodent neuropathic and inflammatory pain models. Translation to humans has been mixed, and a landmark 2016 clinical trial of a FAAH inhibitor in France produced serious off-target toxicity unrelated to FAAH, an instructive reminder that indirect ECS pharmacology is not interchangeable with direct phytocannabinoid dosing.
CBD, FAAH, and the Indirect-Phytocannabinoid Question
CBD does not bind CB1 or CB2 with high affinity, which is why it does not produce a THC-like high. Its pharmacology is indirect: at micromolar concentrations, CBD inhibits FAAH (raising anandamide), modulates TRPV1 and several serotonin receptors, and acts as an allosteric modulator of CB1 — changing the receptor's response to other ligands without activating it. The clinically meaningful downstream effect, in research models, is often framed as "more anandamide available at the synapse for longer."
This framing is what makes CBD products especially relevant to a post about endocannabinoid biology. A well-formulated CBD oil or capsule is, in mechanistic terms, a slow indirect FAAH modulator combined with a TRPV1 agonist and a CB1 allosteric modulator. It is not a THC surrogate. The research portfolio on phytocannabinoid-based wellness products is curated by the PMC CBD pharmacology archive; the preclinical case is strong, and the human clinical case is being built one indication at a time.
South African Context: SAHPRA, Scheduling, and Quality
In South Africa, cannabidiol preparations containing less than 0.001 percent THC and a daily dose not exceeding 20 mg have, since 2024, been moved out of schedule 6 of the Medicines and Related Substances Act into a less restrictive category for general sale, while higher-dose and THC-containing preparations remain scheduled and require a Section 21 application through SAHPRA. The regulatory distinction matters for the active consumer: low-dose CBD isolates and broad-spectrum oils sit on the open market, while full-spectrum and THC-containing products remain in the prescription channel.
Quality assurance is the variable that is hardest to standardise in an emerging category. Independent third-party certificates of analysis (CoAs) for cannabinoid content, terpene profile, residual solvents, heavy metals, and microbial contamination are the practical signal that a product matches its label. BioMuti's 1000 mg CBD oil, for example, ships with batch-tested CoAs and is formulated as a phytocannabinoid-rich broad-spectrum extract — meaning the minor cannabinoids, terpenes, and flavonoids of the source plant remain in the carrier oil. That composition is closer to the "ensemble" approach the original ECS researchers were studying than a CBD-isolate tincture is.
Supporting the ECS Without a Cannabinoid: Lifestyle Levers
The most under-appreciated lever on endogenous anandamide is exercise. Aerobic exercise raises circulating anandamide in humans — the so-called "runner's high" is now understood to be endocannabinoid-mediated rather than purely endorphin-mediated. The relevant studies are summarised in the PubMed exercise-endocannabinoid collection, with effects visible after roughly 30 minutes of moderate-to-vigorous aerobic work.
Diet contributes via the precursor pool. Anandamide is synthesised from arachidonic acid, an omega-6 fatty acid, and the broader endocannabinoid tone is shaped by the ratio of omega-6 to omega-3 intake. Chronic omega-3 enrichment has been shown in animal models to shift 2-AG and anandamide levels in the direction associated with lower anxiety-like behaviour. Sleep deprivation, by contrast, dysregulates CB1 signalling in the prefrontal cortex — one of several reasons the broader BioMuti conversation about sleep architecture keeps returning to ECS tone.
Where the Research Goes Next
Three directions are worth watching. First, allosteric modulators of CB1 (positive modulators rather than antagonists) have shown anxiolytic and analgesic effects in preclinical work without the psychiatric side effects that derailed rimonabant. Second, peripherally-restricted CB1 and CB2 ligands are being explored for liver fibrosis, metabolic syndrome, and neuropathic pain. Third, the "microbiota-gut-brain axis" conversation now intersects with ECS pharmacology: gut bacteria produce endocannabinoid-like lipids that influence mucosal immunity and vagal signalling. Each of these areas has its own pipeline of registered clinical trials.
For South African consumers and researchers, the practical takeaway is that the endocannabinoid system is not a single switch labelled "relax" — it is a layered lipid signalling network with at least two endogenous agonists, two principal receptors, an extended pharmacology across TRP and PPAR channels, and an indirectly accessible pharmacology through compounds like CBD. BioMuti's phytocannabinoid range is built around that layered model: broad-spectrum extracts that preserve the ensemble, batch-tested for label accuracy, and dispensed within the SAHPRA framework that governs the South African market.
Anandamide was named for bliss, but the system it sits inside is closer to a thermostat than a light switch — sensitive to sleep, food, movement, and stress, and responsive to a careful choice of inputs. The next decade of ECS research will not change that thermostat metaphor; it will refine where the dials are.
